Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Breast cancer early disease

Assess patients for signs and symptoms related to breast cancer in early and late stages of the disease. [Pg.1303]

The goal of therapy with early and locally advanced breast cancer is to cure the disease. Breast cancer is currently incurable after it has advanced beyond local-regional disease. The goal of treatment of metastatic breast cancer is to improve symptoms, maintain quality of life, and extend survival. Thus it is important to choose therapy with good activity while minimizing toxicities. Treatment of metastatic breast cancer with either cytotoxic or endocrine therapy often results in regression of disease and improvements in quality of life. [Pg.1315]

Breast cancer has a very high incidence in women. Breast cancer frequently develops into (or is) a systemic disease. The best way to reduce risk due to breast cancer is early tumor detection and surgical removal. The increase in detection rate of breast tumors that are < 1 cm in diameter over the past 10 years can be mostly attributed to improvements in the sensitivity and utilization of mammography. The main utility of CA 15-3 in breast cancer is to monitor patients after mastectomy (14). [Pg.192]

The oral estrogen-alone arm was stopped early after a mean of 7 years of follow-up. Estrogen-only therapy had no effect on coronary heart disease risk and caused no increase in breast cancer risk. [Pg.355]

Breast cancer cells often spread undetected by contiguity, lymph channels, and through the blood early in the course of the disease, resulting in metastatic disease after local therapy. The most common metastatic sites are lymph nodes, skin, bone, liver, lungs, and brain. [Pg.692]

Hormone therapy has proven highly effective in controlling the menopausal syndrome, especially severe hot flushes (MacLennan et al. 2004), even at doses significantly lower than those used until now (Speroff et al. 2000 Utian et al. 2001). Women s Health Initiative studies found that hormone replacement therapy, when administered as a primary prevention intervention for CVD in older women, increases the risk of heart disease and breast cancer. Even if a protective effect on fracture and colon cancer was observed, the risk-benefit ratio led to a recommendation of this treatment only for the short-term relief of menopausal symptoms (Rossouw et al. 2002 Anderson et al. 2004). The role of early administration of ovarian hormones to young postmenopausal women in the prevention of cardiovascular disease or late dementia remains... [Pg.346]

For many common diseases, subsets of cases exist in which genetic factors play an especially important role. These subsets tend to develop disease early in life (e.g., BRCAl and BRCA2 mutations in breast cancer), and they often tend to have a more severe expression of the disease (e.g., APC mutations in colon cancer). [Pg.343]

Individuals at risk for developing a genetic disease with a delayed age of onset may wish to learn whether they have inherited a disease-causing mutation (e.g., Huntington disease, femilial breast cancer, hemochromatosis, adenomatous polyposis coli). In some cases, presymptomatic diagnosis can be highly usefiil in preventing serious disease consequences before they occur (e.g., phlebotomy for hemochromatosis, early tumor detection for familial breast cancer). [Pg.348]

Currently, anastrozole and letrozole are efficacious in early-stage, locally advanced, and mefasfafic disease and fhus they present with the most complete data set for the different stages of breast cancer. Although it seems rather unlikely that one will be able to detect differences with respect to clinical effects at the tumour level, the indirect comparison of different AIs suggests a stronger evidence for the use of exemestane compared with other AIs for breast cancer therapy [90]. [Pg.40]

The roles of tamoxifen and the aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women have been reviewed, distinguishing three approaches replacement of tamoxifen as adjuvant therapy for 5 years (early adjuvant therapy) sequencing of tamoxifen before or after an aromatase inhibitor during the first 5 years (early sequential adjuvant therapy) or the use of an aromatase inhibitor after 5 years of tamoxifen (extended adjuvant therapy) (21). Briefly, the conclusions were that at the time of the survey there was little to choose between the three methods in terms of the balance of benefit and harm. However, like others, the authors stressed that agents of this type are proving to be superior to tamoxifen in preventing recurrence of the disease. [Pg.302]

Breast cancer cytosols Immunoassay Overexpressed in younger patients with early-stage disease, small ER - positive, low S-phase, low-cellularity diploid tumors Associated with a longer DFS and OSc Independent indicator of increased DFS for all patients as well as node-positive, ER-negative Favorable prognosis [269]... [Pg.54]


See other pages where Breast cancer early disease is mentioned: [Pg.91]    [Pg.294]    [Pg.117]    [Pg.220]    [Pg.221]    [Pg.221]    [Pg.134]    [Pg.1307]    [Pg.1307]    [Pg.1309]    [Pg.1310]    [Pg.344]    [Pg.342]    [Pg.163]    [Pg.248]    [Pg.391]    [Pg.44]    [Pg.45]    [Pg.52]    [Pg.157]    [Pg.220]    [Pg.10]    [Pg.232]    [Pg.713]    [Pg.288]    [Pg.347]    [Pg.18]    [Pg.574]    [Pg.294]    [Pg.241]    [Pg.284]    [Pg.320]    [Pg.329]    [Pg.581]    [Pg.119]    [Pg.1277]    [Pg.1306]    [Pg.1313]    [Pg.1317]   
See also in sourсe #XX -- [ Pg.1307 , Pg.1308 , Pg.1308 , Pg.1309 , Pg.1310 , Pg.1311 , Pg.1312 , Pg.1313 , Pg.1314 ]




SEARCH



Disease breast

Diseases cancer

© 2024 chempedia.info